Total Payments
$2,209
2024 Payments
$17.79
Companies
25
Transactions
131
Medicare Patients
1,386
Medicare Billing
$618,871
Payment Breakdown by Category
Food & Beverage$1,922 (87.0%)
Travel$285.07 (12.9%)
Education$2.56 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,922 | 129 | 87.0% |
| Travel and Lodging | $285.07 | 1 | 12.9% |
| Education | $2.56 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Collegium Pharmaceutical, Inc. | $549.94 | 28 | $0 (2024) |
| DePuy Synthes Products, Inc. | $285.07 | 1 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $237.45 | 35 | $0 (2022) |
| Purdue Pharma L.P. | $193.15 | 13 | $0 (2018) |
| BioDelivery Sciences International, Inc. | $142.97 | 7 | $0 (2021) |
| Pernix Therapeutics Holdings, Inc. | $113.44 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $86.83 | 5 | $0 (2018) |
| Lilly USA, LLC | $80.47 | 4 | $0 (2020) |
| Sentynl Therapeutics, Inc. | $69.63 | 4 | $0 (2017) |
| Horizon Therapeutics plc | $60.36 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.79 | 1 | Collegium Pharmaceutical, Inc. ($17.79) |
| 2023 | $75.53 | 4 | Collegium Pharmaceutical, Inc. ($55.85) |
| 2022 | $77.73 | 5 | Collegium Pharmaceutical, Inc. ($41.72) |
| 2021 | $210.29 | 13 | Collegium Pharmaceutical, Inc. ($63.31) |
| 2020 | $179.18 | 9 | Collegium Pharmaceutical, Inc. ($155.68) |
| 2019 | $421.07 | 9 | DePuy Synthes Products, Inc. ($285.07) |
| 2018 | $300.28 | 17 | BioDelivery Sciences International, Inc. ($112.16) |
| 2017 | $927.32 | 73 | Collegium Pharmaceutical, Inc. ($198.44) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/13/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.79 | General |
| Category: Opioid Analgesic | ||||||
| 11/08/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: INSOMNIA | ||||||
| 10/30/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.06 | General |
| Category: Opioid Analgesic | ||||||
| 04/05/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.28 | General |
| Category: Opioid Analgesic | ||||||
| 02/14/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $19.51 | General |
| Category: Opioid Analgesic | ||||||
| 11/01/2022 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $16.72 | General |
| Category: Opioid Analgesic | ||||||
| 03/11/2022 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.67 | General |
| Category: AED | ||||||
| 01/24/2022 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.67 | General |
| Category: AED | ||||||
| 01/12/2022 | Horizon Therapeutics plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: DUEXIS | ||||||
| 01/10/2022 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Opioid Analgesic | ||||||
| 12/09/2021 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $13.33 | General |
| Category: AED | ||||||
| 11/30/2021 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: AED | ||||||
| 11/22/2021 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Neuroscience | ||||||
| 11/02/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2021 | BioDelivery Sciences International, Inc. | BELBUCA (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Chronic Pain | ||||||
| 09/27/2021 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.23 | General |
| Category: Opioid Analgesic | ||||||
| 09/15/2021 | Horizon Therapeutics plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: DUEXIS | ||||||
| 09/01/2021 | Horizon Therapeutics plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: DUEXIS | ||||||
| 08/11/2021 | Horizon Therapeutics plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: DUEXIS | ||||||
| 07/14/2021 | Horizon Therapeutics plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: DUEXIS | ||||||
| 06/14/2021 | BioDelivery Sciences International, Inc. | BELBUCA (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Chronic Pain | ||||||
| 05/24/2021 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $24.46 | General |
| Category: Opioid Analgesic | ||||||
| 01/26/2021 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: Opioid Analgesic | ||||||
| 12/08/2020 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.29 | General |
| Category: Opioid Analgesic | ||||||
| 11/10/2020 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.48 | General |
| Category: Opioid Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 262 | 1,196 | $349,188 | $119,757 |
| 2022 | 7 | 328 | 1,419 | $417,322 | $143,833 |
| 2021 | 8 | 366 | 1,700 | $429,407 | $175,901 |
| 2020 | 9 | 430 | 1,967 | $496,024 | $179,381 |
Total Patients
1,386
Total Services
6,282
Medicare Billing
$618,871
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 978 | $271,493 | $93,154 | 34.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $21,067 | $7,906 | 37.5% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 21 | 34 | $19,638 | $6,623 | 33.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 30 | 62 | $13,526 | $4,977 | 36.8% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 16 | 16 | $10,377 | $3,763 | 36.3% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 14 | 15 | $8,387 | $3,056 | 36.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 27 | 47 | $4,700 | $278.72 | 5.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 1,121 | $311,190 | $107,354 | 34.5% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2022 | 31 | 60 | $34,701 | $12,994 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 51 | 51 | $24,393 | $8,551 | 35.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 38 | 67 | $14,617 | $5,508 | 37.7% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2022 | 23 | 23 | $14,917 | $5,494 | 36.8% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 16 | 17 | $9,505 | $3,530 | 37.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 38 | 80 | $8,000 | $402.05 | 5.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 167 | 1,405 | $330,122 | $139,033 | 42.1% |
| 62323 | Injection of substance into spinal canal of lower back or sacrum using imaging guidance | Office | 2021 | 33 | 59 | $32,802 | $12,964 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $17,099 | $7,137 | 41.7% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 36 | 57 | $11,756 | $4,974 | 42.3% |
| 95913 | Nerve transmission studies, 13 or more studies | Office | 2021 | 17 | 17 | $10,991 | $4,410 | 40.1% |
| 62321 | Injection of substance into spinal canal of upper or middle back using imaging guidance | Office | 2021 | 12 | 18 | $10,074 | $4,060 | 40.3% |
| 95912 | Nerve transmission studies, 11-12 studies | Office | 2021 | 13 | 13 | $7,264 | $2,907 | 40.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2021 | 50 | 93 | $9,300 | $415.54 | 4.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 167 | 1,558 | $361,282 | $131,755 | 36.5% |
| 62323 | Injection of substance into spinal canal of lower back or sacrum using imaging guidance | Office | 2020 | 39 | 81 | $43,994 | $17,336 | 39.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 46 | 46 | $20,636 | $7,399 | 35.9% |
About Dr. Wayne Kelly, MD
Dr. Wayne Kelly, MD is a Interventional Pain Medicine healthcare provider based in Rolling Meadows, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164519005.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wayne Kelly, MD has received a total of $2,209 in payments from pharmaceutical and medical device companies, with $17.79 received in 2024. These payments were reported across 131 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($1,922).
As a Medicare-enrolled provider, Kelly has provided services to 1,386 Medicare beneficiaries, totaling 6,282 services with total Medicare billing of $618,871. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Location Rolling Meadows, IL
- Active Since 10/10/2006
- Last Updated 02/10/2018
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1164519005
Products in Payments
- XTAMPZA (Drug) $331.99
- TROKENDI XR (Drug) $237.45
- Xtampza ER (Drug) $183.10
- ZOHYDRO ER (Drug) $113.44
- BELBUCA (Drug) $113.31
- HYSINGLA ER (Drug) $88.74
- EMGALITY (Drug) $80.47
- DUEXIS (Drug) $76.67
- Levorphanol (Drug) $69.63
- Morphabond ER (Drug) $46.54
- Symproic (Drug) $45.75
- MOVANTIK (Drug) $42.14
- SUBOXONE SUBLINGUAL FILM (Drug) $40.43
- Movantik (Drug) $40.29
- LYRICA (Drug) $37.03
- Evzio (Drug) $35.08
- BUNAVAIL 2.1 mg 30-count box (Drug) $29.66
- OXYCONTIN (Drug) $25.08
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $24.78
- Aimovig (Biological) $22.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.